| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 10/19/2006 | WO2006109084A1 Dna-pk inhibitors |
| 10/19/2006 | WO2006109081A1 Dna-pk inhibitors |
| 10/19/2006 | WO2006109026A1 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors |
| 10/19/2006 | WO2006108844A1 Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab) |
| 10/19/2006 | WO2006108763A1 Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors |
| 10/19/2006 | WO2006108670A2 Use of cd25 antibodies in immunotherapy |
| 10/19/2006 | WO2006108640A1 Phenylacetamides suitable as protein kinase inhibitors |
| 10/19/2006 | WO2006108489A1 Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
| 10/19/2006 | WO2006108488A1 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents |
| 10/19/2006 | WO2006108487A1 (lh-ind0l-7-yl)-( (pyrimidin-2 -yl-amino) methanone derivatives and related compounds as igf-rl inhibitors for treating cancer |
| 10/19/2006 | WO2006108482A1 Purine derivatives as receptor-tyrosine kinase activityinhibitors |
| 10/19/2006 | WO2006108429A1 Nutrient composition for treating sarcoma and prostate cancer |
| 10/19/2006 | WO2006108428A1 A process for the preparation of an oxaliplatin preparation |
| 10/19/2006 | WO2006108276A1 A method of treating cancer using dichloroacetate |
| 10/19/2006 | WO2006108270A1 Inhibitors of protein kinases and uses thereof |
| 10/19/2006 | WO2006108225A1 Method of screening for compounds that modulate cell proliferation |
| 10/19/2006 | WO2006091693A3 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor |
| 10/19/2006 | WO2006083979A3 Local treatment of neurofibromas |
| 10/19/2006 | WO2006082428A3 Combination therapies using hdac inhibitors |
| 10/19/2006 | WO2006081230A3 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer |
| 10/19/2006 | WO2006079121A3 Methods of treating disease with glycosylated interferon |
| 10/19/2006 | WO2006077407A3 Modulators of itch ubiquitinase activity |
| 10/19/2006 | WO2006069395A3 Synthetic process for the preparation of biocyclic compounds |
| 10/19/2006 | WO2006035204A3 Combination comprising zd6474 and an imatinib |
| 10/19/2006 | WO2005102367A3 Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer |
| 10/19/2006 | WO2005014542A3 Novel n-substituted indolyl-3-glyoxylic acid amides, use thereof as a medicament against cancer, and method for the production thereof |
| 10/19/2006 | US20060235231 Histone deacetylase inhibitors |
| 10/19/2006 | US20060235223 Variolin derivatives and their use as antitumor agents |
| 10/19/2006 | US20060235201 Enduring T cell response |
| 10/19/2006 | US20060235132 Method of preparing poly(vinyl pivalate) by low temperature suspension-polymerization of vinyl pivalate, and poly(vinyl pivalate) and poly(vinyl alcohol) prepared using same |
| 10/19/2006 | US20060235061 Methods of using benzothiophenone derivatives to treat cancer or inflammation |
| 10/19/2006 | US20060235059 administering two or more timed doses of 7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methylsulfanyl-thiazol-4-yl)-vinyl]-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione also called epothilone b; treating a drug resistant tumor |
| 10/19/2006 | US20060235058 Substituted 5-membered ring compounds and their use |
| 10/19/2006 | US20060235054 e.g. 3-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)imidazole-2-thione; immunomodulating and cytokine-release-inhibiting action; antiinflammatory agent |
| 10/19/2006 | US20060235033 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor |
| 10/19/2006 | US20060235027 Inhibitors of cdc25 phosphatases |
| 10/19/2006 | US20060235025 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 10/19/2006 | US20060235023 Inhibitors of macrophage migration inhibitory factor and methods for indentifying the same |
| 10/19/2006 | US20060235012 Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
| 10/19/2006 | US20060235002 Novel physiologically active substance |
| 10/19/2006 | US20060234999 Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration |
| 10/19/2006 | US20060234990 Compositions of boswellic acids derived from Boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 10/19/2006 | US20060234985 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
| 10/19/2006 | US20060234984 Mitotic kinesin inhibitors |
| 10/19/2006 | US20060234975 Use of adenosine receptor agonists in therapy |
| 10/19/2006 | US20060234937 Modulation of angiogenesis |
| 10/19/2006 | US20060234929 Rasgap derived peptide for selectively killing cancer cells |
| 10/19/2006 | US20060234928 Cell death-inducing fused gene acting specifically on cancer and gene product thereof |
| 10/19/2006 | US20060234909 Compositions and methods for increasing drug efficiency |
| 10/19/2006 | US20060234904 Method for preparing polymorphism of irinotecan hydrochloride |
| 10/19/2006 | US20060234344 Protein kinases |
| 10/19/2006 | US20060234343 deletion of residues in the CR2 domain of the EGFR ectodomain gives rise to a truncated ectodomain with enhanced affinity for epidermal growth factors such as (EGF) and/or transforming growth factor-I (TGF- alpha ); psoriasis and tumor states |
| 10/19/2006 | US20060234342 Human DNA topoisomerase I alpha |
| 10/19/2006 | US20060234307 Fusion proteins of of Fc domains with Ang-2 binding peptides; increases biological half life; angiopoietin-2 (Ang-2) |
| 10/19/2006 | US20060234286 Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses |
| 10/19/2006 | US20060234271 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 10/19/2006 | US20060234239 An oligonucleotide targeted to (hybridizing with) a nucleic acid molecule encoding human insulin like growth factor I receptor; treatment of proliferative and inflammatory skin disorders and cancer |
| 10/19/2006 | US20060234224 Method and nucleic acids for the analysis of colon cell proliferative disorders |
| 10/19/2006 | US20060233899 Treatment of Human Multiple Myeloma by Curcumin |
| 10/19/2006 | US20060233877 Betaine compositions |
| 10/19/2006 | US20060233820 Inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression; cancers associated with an infection |
| 10/19/2006 | US20060233816 Use of plant oil-bodies in vaccine delivery systems |
| 10/19/2006 | US20060233813 Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
| 10/19/2006 | US20060233811 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 10/19/2006 | US20060233807 Novel therapies and methods of screening for therapeutic compounds |
| 10/19/2006 | US20060233806 Removal promoters and inhibitor for apoptosis cells in vivo |
| 10/19/2006 | US20060233804 IGF antagonist peptides |
| 10/19/2006 | US20060233796 Method of modulating memory effector T-cells and compositions |
| 10/19/2006 | US20060233792 novel tumor necrosis factor receptor (TRAIN-R) for treating inflammatory bowel disease and arthritic condition; antiinflammatory agents |
| 10/19/2006 | US20060233780 Method for treating oncological diseases |
| 10/19/2006 | US20060233756 Recombinant adenoviral vectors and applications thereof |
| 10/19/2006 | US20060233753 Administering an adenovirus defective in its VAI and VAII virus-associated RNAs |
| 10/19/2006 | US20060233746 N-terminally chemically modified protein compositions and methods |
| 10/19/2006 | US20060233742 cyclic peptides blocking of the Casein Kinase II (CKII) phosphorylation domain; HPV-16 cervical carcinoma cells; peptides increase the sensitivity of the cells to the cytostatic effect of IFN |
| 10/19/2006 | US20060233707 Process for producing an injectable medicament preparation |
| 10/19/2006 | US20060233704 Prochelator for the preparation of radiometal labeled molecules having improved biological properties |
| 10/19/2006 | DE202006001133U1 Multifunctional active agent mixture, useful as auxiliary material in virus vaccine or vaccine to treat cancer, comprises fraction of specific peptide in polypetide chain and fraction with essential and non-essential amino acids |
| 10/19/2006 | DE112004001502T5 Neurobeschützende und Anti-Proliferationsverbindungen Neurobeschützende and anti-proliferative compounds |
| 10/19/2006 | DE102005018641A1 Use of ester compounds and/or compounds that are converted to ester compounds in the organism, in the preparation of a medicament for the inhibition of cell proliferation by inhibiting the reaction of glyoxalase I and/or II |
| 10/19/2006 | DE102005017551A1 Recovery, preparation and storage of stem cells from umbilical cord blood, useful e.g. for autologous treatment of anemias, cancer, AIDS and thalassemia |
| 10/19/2006 | DE102005016873A1 New nano-particle useful for production of composition to treatment and/or prophylaxis of proliferative illnesses, cancer and bacterial infections, where nano-particle is bonded therapeutic substance |
| 10/19/2006 | DE102005016634A1 Neuartige Aza-Hetercyclen als Kinase-Inhibitoren Novel aza-heterocycles as kinase inhibitors |
| 10/19/2006 | CA2604895A1 (1h-indol-7-yl)-( (pyrimidin-2-ylamino) methanone derivatives and related compounds as igf-r1 inhibitors for the treatment of cancer |
| 10/19/2006 | CA2604862A1 A process for the preparation of an oxaliplatin preparation |
| 10/19/2006 | CA2604822A1 Novel process for producing ramosetron or its salt |
| 10/19/2006 | CA2604640A1 Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| 10/19/2006 | CA2604625A1 A method of treating cancer using dichloroacetate |
| 10/19/2006 | CA2604542A1 Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
| 10/19/2006 | CA2604536A1 Conjugate comprising p21 protein for the treatment of cancer |
| 10/19/2006 | CA2604294A1 Purine derivatives as inhibitors of receptor tyrosine kinase activity |
| 10/19/2006 | CA2604198A1 Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab) |
| 10/19/2006 | CA2603941A1 Phenylacetamides suitable as protein kinase inhibitors |
| 10/19/2006 | CA2603860A1 Cytotoxic compounds and conjugates comprising duocarmycins with cleavable substrates |
| 10/19/2006 | CA2603780A1 Sema4d in cancer diagnosis, detection and treatment |
| 10/19/2006 | CA2603637A1 Dna-pk inhibitors |
| 10/19/2006 | CA2603634A1 Novel isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein hsp90 activities |
| 10/19/2006 | CA2603457A1 Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof |
| 10/19/2006 | CA2603402A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| 10/19/2006 | CA2603204A1 Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
| 10/19/2006 | CA2602721A1 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors |